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Abstract
Background
Access to an accurate diagnostic test for Buruli ulcer (BU) is a research priority according to
the World Health Organization. Nucleic acid amplification of insertion sequence IS2404 by
polymerase chain reaction (PCR) is the most sensitive and specific method to detect Myco-
bacterium ulcerans (M. ulcerans), the causative agent of BU. However, PCR is not always
available in endemic communities in Africa due to its cost and technological sophistication.
Isothermal DNA amplification systems such as the recombinase polymerase amplification
(RPA) have emerged as a molecular diagnostic tool with similar accuracy to PCR but having
the advantage of amplifying a template DNA at a constant lower temperature in a shorter
time. The aim of this study was to develop RPA for the detection of M. ulcerans and evaluate
its use in Buruli ulcer disease.
Methodology and principal findings
A specific fragment of IS2404 of M. ulcerans was amplified within 15 minutes at a constant
42˚C using RPA method. The detection limit was 45 copies of IS2404 molecular DNA
standard per reaction. The assay was highly specific as all 7 strains of M. ulcerans tested
were detected, and no cross reactivity was observed to other mycobacteria or clinically
relevant bacteria species. The clinical performance of the M. ulcerans (Mu-RPA) assay
was evaluated using DNA extracted from fine needle aspirates or swabs taken from 67
patients in whom BU was suspected and 12 patients with clinically confirmed non-BU
lesions. All results were compared to a highly sensitive real-time PCR. The clinical speci-
ficity of the Mu-RPA assay was 100% (95% CI, 84–100), whiles the sensitivity was 88%
(95% CI, 77–95).
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Conclusion
The Mu-RPA assay represents an alternative to PCR, especially in areas with limited
infrastructure.
Author summary
Current diagnostic methods to detect M. ulcerans suffer from delayed time-to-results in
most endemic countries by the prolonged period of time for the shipment and storage of
samples to a distant, centralized laboratory. The M. ulcerans recombinase polymerase
amplification assay (Mu-RPA) is a new, rapid diagnostic test developed for the detection
of M. ulcerans infection, known commonly as Buruli ulcer, a chronic, debilitating, necro-
tizing disease of the skin and soft tissues. This assay is suitable for use on a portable
detection device, with the potential to be used for quick diagnosis at the point of need,
providing timely results to health workers at Buruli ulcer treatment clinics.
Introduction
Buruli ulcer (BU) is a neglected tropical disease caused by M. ulcerans. The pathogenesis of BU
is linked to the production of a polyketide toxin known as mycolactone which is cytotoxic and
has immunomodulatory properties [1]. The disease affects mostly children and adults of all
ages and presents as nodules, plaques, ulcers and oedema. There is a wide differential diagnosis
ranging from lipomas, ganglion, onchocerciasis nodules, and fungal lesions for non-ulcerated
lesions to tropical, diabetic or vascular ulcers in the case of ulcerated lesions so it is vital that
accurate diagnosis should be available close to patients in rural West Africa [2,3].
Currently, there are no preventive strategies against BU as the mode of transmission
remains unknown and there is no vaccine. However, antimicrobial therapy with a combina-
tion of rifampicin and streptomycin or clarithromycin has proven effective in healing all forms
of the disease and reducing the recurrence rate to less than 2% [4–6]. As a result, early diagno-
sis of clinically suspected cases has become a critical step in the clinical management of BU in
order to prevent misdiagnosis and administration of unnecessary antibiotics [7].
The gold standard diagnostic tool for BU is PCR for the repeat sequence IS2404, which is
specific to M. ulcerans [8]. Microscopy for acid fast bacilli and culture for M. ulcerans have low
sensitivity and histopathology is rarely available in endemic areas. Although PCR has high sen-
sitivity (up to 95%) it has to be performed in a reference laboratory, often far from the endemic
area, due to the need for a sophisticated laboratory setup and skilled personnel which may not
be available in endemic communities [9]. Difficulties with sample collection and transporta-
tion may lead to a slow turnaround resulting in delayed treatment and an increase in costs. A
field friendly diagnostic tool would bring diagnosis closer to the patients, thereby reducing
costs and bringing forward the start of treatment.
Recently, isothermal amplification techniques such as loop-mediated amplification
(LAMP) have been proposed as an alternative to PCR for diagnosis of BU [9,10]. Unlike PCR,
isothermal amplification techniques do not require a thermocycler and yield readily readable
results within a short turnaround time. Recombinase polymerase amplification (RPA) has
emerged as a novel isothermal technique in molecular diagnosis of various infectious diseases
[11] including tuberculosis [12,13] and paratuberculosis (Johne’s disease) [14]. Compared to
PCR and other isothermal techniques RPA is more rapid (less than 20 min) and simpler to run
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as it requires a lower temperature (37–42˚C) [11]. This technique opens the door to extending
molecular diagnosis in fieldwork and at the point of care.
In this study, we developed a real-time isothermal RPA assay for the detection of M. ulcer-
ans as an alternative to PCR. The efficiency of the assay as a diagnostic tool was determined by
testing its sensitivity and specificity with clinical samples from suspected patients.
Materials and methods
Preparation of molecular standard
To generate a molecular standard that will be used as positive control and a calibration tem-
plate with known copy numbers, a 451 bp fragment of IS2404 sequence covering the nucleo-
tides 96540 to 96990 (Genbank accession no. CP000325.1) was synthesised by GeneArt Gene
Synthesis (Invitrogen, Regensburg, Germany). A dilution range of 100 to 106 copies/μl of the
standard was prepared.
DNA extraction from bacterial strains and clinical samples
Genomic DNA was derived from mycobacterial strains obtained from Belgian Co-Ordinated
Collections of Micro-organisms, Institute of Tropical Medicine (BCCM/ITM Mycobacteria
Collection, Antwerp, Belgium). DNA was extracted from pure colonies following culture on
Lowenstein-Jensen slant Medium (BD, Franklin Lakes, NJ, USA) for 4–6 weeks. Colonies were
suspended in 700 μl of Cell Lysis solution (CLS) (Qiagen, Hilden, Germany) and stored in a
fridge until ready for extraction. Similarly, swabs and fine-needle aspirates obtained from
ulcerative and non-ulcerative lesions respectively were collected directly into 700 μl CLS. M.
ulcerans DNA was extracted using the Gentra Puregene DNA isolation kit (Qiagen, Hilden,
Germany) following manufacturer’s instructions with minor modifications as previously
described [15]. The QIAamp DNA Mini Kit (Qiagen) was used for isolation of DNA from 5
bacterial species frequently colonizing human skin following manufacturer’s instruction. The
amount of DNA was measured with a DeNovix DS-11 Spectrophotometer (DeNovix Inc., Wil-
mington, USA).
Real-time PCR
Real-time PCR was run on a Rotor-Gene Q (Qiagen, Hilden, Germany) using the Hot FIREPol
Probe qPCR Mix Plus to amplify a 59 bp long fragment (Nucleotide 96627 to 96685 of the
GenBank accession number CP000325.1) (see Table 1). The PCR reaction volume was 20 μl
containing 1 μl each of 10 μM IS2404 TF and IS2404 TR, 1 μl of 5 μM IS2404 TP2, 4 μl of 5 U/
μl qPCR Mix Plus, 2 μl of 10x Exo IPC Mix, 0.4 μl Exo IPC DNA and 8.6 μl Molecular grade
H2O as well as 2 μl of the DNA template. The PCR cycling conditions were adopted from a
published assay [16] as follows: Initial denaturation for 15 minutes at 95˚C, then 40 cycles of
95˚C for 15 seconds and 60˚C for 60 seconds with fluorescence activation. Each batch of sam-
ples run included negative extraction control, no template control (NTC) and positive control.
All the negative extraction controls and NTC did not show an amplification curve. This indi-
cated that there were no contamination during preparation of the PCR master mixes or during
the DNA extraction process. All samples that did not show an amplification curve above the
set threshold were considered negative. Similarly, the internal positive control (IPC) and the
positive controls showed exponential amplification curves. All samples with an exponential
amplification curve with the cycle threshold (CT) less than 40, was considered positive.
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RPA assay design and conditions
The Mu-RPA assay was designed to target the insertion sequence IS2404 which has been
shown to have high sensitivity and specificity for diagnosing BU. Primers were designed using
the recommendations given in the TwistDx instruction manual [17] and Primer-BLAST avail-
able at http://www.ebi.ac.uk/ena/data/sequence/search combining Primer3 and BLAST global
alignment. Oligonucleotide primers and probes were synthesized by TIB MOLBIOL (Berlin,
Germany). Preliminary screening of 3 forward primers and 3 reverse primer combinations
were tested with the Twist Amp Basic “Improved Formulation” kits according to the manufac-
turer’s instructions (TwistDx Ltd., UK) in a final reaction volume of 50 μl. Briefly, 29.5 μl
Rehydration buffer, 8.2 μl H2O, 2.4 μl of 5 μM of both forward and reverse primer and 5 μl of
the DNA template were added to a freeze dried reaction pellet. Water was used for the negative
control. The RPA reactions were incubated at 42 ˚C for 15 minutes following the addition of
2.5 μl 280 mM MgAc. The template used was 1 ng/μL of Mu strain (ITM 063846). One primer
pair producing a 217 bp fragment of gene IS2404 sequence covering nucleotides 96641–96857
(Genbank accession CP000325.1) was selected (Table 1) after analysis of amplicons by agarose
gel electrophoresis (AGE).
In the case of real-time RPA detection, TwistAmp Exo “Improved Formulation” kit
(TwistDX Ltd, Cambridge, UK) was used according to the protocol described dx.doi.org/10.
17504/protocols.io.vvve666. Fluorescence detection at 570 nm for FAM channel was measured
and a threshold set by increasing the fluorescence above the 3 standard deviations over the
background detected in the first minute of incubation. We programmed the T8- fluorometer
using the T8-ISO Desktop application (Axxin Pty Ltd, Victoria, Australia) to detect the lowest
dilutions that met criteria for distinguishing positive samples from negative controls based on
serial dilutions of the molecular standard. All tests were run at 42 ˚C for 900 seconds (15 min-
utes) with mixing after 4 minutes. To be considered positive, a sample required either an
amplitude or gradient of at least 900 mV over a 40 second sliding window during the amplifi-
cation phase of the test (300–900 seconds).
Analytical sensitivity and specificity
To determine the analytical sensitivity, 5 μl and 2 μl of a dilution range 106–100 copies/μl of
quantitative IS2404 DNA fragment standard was tested six times in triplicates with Mu-RPA
and the real-time PCR, respectively. The threshold time (TT) and the cycle threshold (CT)
values were plotted against the number of molecules detected. Non-regression analysis and
probit analysis was done by GraphPad Prism (GraphPad software, San Diego, USA). The
Table 1. Primers and probes for the RPA and real-time PCR for amplification and detection of Mycobacterium ulcerans.
Primer/
Probe
Sequence (5’-3’) Gene target Nucleotide position Amplicon size Reference
IS2404TF AAA GCA CCA CGC AGC ATC T IS2404 96685–96667 [16]
IS2404TR AGC GAC CCC AGT GGA TTG 96627–96644 59 bp
IS2404TP FAM-CCG TCC AAC GCG ATC GGC A-BBQ 96664–96646
Mu_RPA F1 ATG CAT CGC ATC CAC AGT GAC CAG CCA CCG IS2404 96857–96828 This
studyMu_RPA R2 ATT GGT GCC GAT CGC GTT GGA CGG CAA GAT G 96641–96671 217 bp
Mu_RPA P GTA GGC GAA CAC CGA CAC GAG ATG CGT GGC QTF CGC TTT GGC GCG
TA–PH
96731–96685
QTF are sites of the quencher and fluorophore in the order quencher BHQ1-dt (Q), THF (T) and Fam-dT (F)
FAM, Carboxyfluorescein fluorescent dye; BBQ, BlackBerry Quencher; dT-BHQ1, Black Hole Quencher-1; dT- deoxythymidine; THF, Tetrahydrofuran
https://doi.org/10.1371/journal.pntd.0007155.t001
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limit of detection in 95% of the dilutions was extrapolated from the sigmoid curve. To assess
the specificity of the Mu-RPA assay for the detection of M. ulcerans, 1 ng/μL DNA from
closely related mycobacterial species and bacterial species contaminating the human skin
were tested.
Assessment of RPA performance using clinical samples
RPA was evaluated with DNA extracts isolated from samples previously obtained from
patients referred to BU treatment centres in Ghana. Samples were collected as part of routine
diagnostic procedure. Swabs were obtained from ulcers and fine needle aspirates from non-
ulcerative lesions using standard guidelines [18]. In total, a panel of 79 DNA extracts from 69
clinically suspected BU patients and 12 clinically confirmed non BU ulcers. All samples were
tested with both the real-time PCR and the Mu-RPA assay to determine the clinical sensitivity
and specificity of the assay using real-time PCR as the reference test. Both tests were conducted
independently by two different investigators and were blind to the results of the other test.
Statistics
Microsoft Excel 2016 was used for data management. GraphPad Prism v.6 (GraphPad soft-
ware, San Diego, USA) was used to calculate a semi-log regression of the dataset of repeated
amplification runs of RPA and real-time PCR by plotting the mean threshold time (TT) and
cycle threshold (CT) respectively against molecules detected of the standard DNA dilutions
(106−100 copies/μl). A probit regression analysis was performed to determine the limit of
detection (LOD) in 95% of dilutions for both assays using GraphPad Prism. Descriptive statis-
tics were used to obtain general descriptive information such as median and interquartile
ranges from the data. Contingency tables and receiver operating characteristics (ROC) curve
analysis were employed to calculate the sensitivity, specificity and the predictive values in eval-
uating the assay.
Ethics statement
Ethical approval for this study was obtained from the Committee on Human Research, Publi-
cation and Ethics (CHRPE/AP/122/17) School of Medical Sciences, Kwame Nkrumah Univer-
sity of Science and Technology. A total of 79 samples were included in this study under ethical
consideration. All samples were handled anonymously.
Accession number
Mycobacterium ulcerans Agy99, Complete genome–Genbank accession no. CP000325.1.
Results
RPA assay for M. ulcerans detection
Primers and probes were designed to target the insertion sequence, IS2404, a region that has
been shown to have high sensitivity for diagnosing BU using PCR. The region chosen for the
RPA primer design was overlapping with already published primer binding sites of M. ulcerans
PCR [19]. Designed primers and probes were screened using BLASTN and the NCBI nucleo-
tide database to ensure that target sequences for the designs were exclusive for M. ulcerans
strains. The RPA assay was developed in single tube reactions to screen primers and test differ-
ent reaction conditions. Among 3 forward primers, 3 reverse primers and one probe (P) only
F1+R2 and probe (Table 1) were able to amplify down to 10 DNA molecules per reaction. The
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target region was subjected to a BLAST search (blast.ncbi.nlm.nih.gov) to check for cross-reac-
tivity with non-Mu sequences and no non-Mu sequences were identified.
The detection limit of the Mu-RPA assay was determined by six independent runs of serial
dilutions (106–100 copies/μl) with the molecular standard (Fig 1). Rapid detection was
observed; 5 minutes for the detection of 106 copies, 7 minutes for 103 copies and 12 minutes
for 10 copies. The data were used in semi-regression and probit regression analyses. The assay
was reproducible showing good correlation between copy number and time to detection (Fig
2) but with less efficiency compared to PCR (R2 0.92 versus 0.99 respectively). The limit of
detection in 95% of dilutions was 45 copies (Fig 3).
To determine whether there was any cross-reactivity of the Mu-RPA assay for other
microorganisms other than M. ulcerans, DNA extracts from a panel of 7 non-M. ulcerans
Fig 1. Amplification curves in Mu RPA (A) and BU real-time PCR (B) assays applying serial dilutions (106–1) of the molecular
DNA standard. No fluorescent signals were detected in RPA before four minutes because the strip was taken out for mixing. The
lowest number of copies detected for RPA and real-time PCR was 10 and 1 respectively.
https://doi.org/10.1371/journal.pntd.0007155.g001
Fig 2. Reproducibility of the RPA and real-time PCR assays using data set of 6 runs of serial dilution of the MU molecular
standard. A: Threshold time (Y-axis) was plotted versus the log10 concentration of molecules (X-axis) for the RPA. B: Threshold
cycle (CT) on the Y-axis was plotted versus the log10 concentration of molecules (X-axis) for the real-time PCR. RPA assay produced
results between 5 to 20 minutes. The error bars represent the range. The real-time PCR had a higher efficiency compared to the RPA,
due to the regular cycle format of the PCR, while there is no strict separation of the amplification cycles in the isothermal RPA
technology.
https://doi.org/10.1371/journal.pntd.0007155.g002
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mycobacterial species, 5 bacterial species that commonly colonise the skin and 7 M. ulcerans
strains were tested. No amplification signals were obtained from any of the bacterial DNAs
other than those of the Mu strains (Table 2).
Analysis of diagnostic accuracy
The assay performance as a diagnostic tool was assessed using a panel of 67 DNA samples col-
lected from suspected cases of BU during routine care by an expert and 12 non-BU lesions
clinically confirmed to have other diseases (ie. 3 diabetic foot ulcers, 4 traumatic injuries, 3 cel-
lulitis and 2 surgical site infections). The samples were obtained from patients presenting with
varied lesions: 12 (15%) nodules, 9 (11%) plaques, 1 (2%) edema and 57 (72%) ulcers. It was
made up of 24 (30%) fine needle aspirates (FNA) and 55 (70%) swabs. The characteristics of
cases and the type of samples collected are summarized in Table 3.
All samples were tested by both RPA and real-time PCR. Fifty-eight of these samples were
confirmed by PCR as BU. Of the 58 confirmed cases, 51 were correctly identified by the RPA
assay with 7 false negative results giving a sensitivity of 88% (95% CI, 77–95). The 21 PCR neg-
ative samples were all negative by RPA, specificity of 100% (95% CI, 84–100) and a 100% (95%
CI, 93–100) positive predictive value (PPV) with a Youden’s index of 88% (95% CI, 61–95).
When the analysis was stratified by type of sample, the sensitivity and specificity of the RPA
for swabs in comparison to PCR were 92% (95% CI 78–98) and 100% (95% CI, 82–100) respec-
tively with a 100% (95% CI, 89–100) PPV. Similarly, the sensitivity and specificity of FNA sam-
ples were 82% and 100% (95% CI, 81–100) respectively (See Table 4). The specificity was 100%
for all forms and severity of lesions analyzed. To further assess the reliability of the assay, we
Fig 3. Probit curve used to calculate the limit of detection of the Mu RPA assay. IS2404 DNA fragment standard was tested in
dilution range 106–100 copies/μl of six times for each dilution. Percent detection (Y) was plotted versus log10 concentration. The
limit of detection of RPA at 95% of dilutions is 45 copies/μl was extrapolated from the sigmoid curve.
https://doi.org/10.1371/journal.pntd.0007155.g003
Detection of Mycobacterium ulcerans with recombinase polymerase amplification
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007155 February 1, 2019 7 / 14
Table 2. Bacteria species and strains used for testing cross reactivity of the Mu-RPA assay.
Name of bacteria ITM No. Origin RPA results
Mycobacterium ulcerans 063846 Benin +
Mycobacterium ulcerans C05150 DRC +
Mycobacterium ulcerans C05142 Australia +
Mycobacterium ulcerans C08756 Japan +
Mycobacterium ulcerans 092078 French Guiana +
Mycobacterium ulcerans 070290 China +
Mycobacterium ulcerans 083720 Mexico +
Mycobacterium marinum 12562 −
Mycobacterium tuberculosis 000092 −
Mycobacterium avium 960261 −
Mycobacterium vaccae M001002 −
Mycobacterium africanum M002046 −
Mycobacterium chelonae subsp. Complex 940717 −
Mycobacterium celatum Clinical strain UK −
Staphylococcus aureus ATCC 25923� −
Escherichia coli ATCC 25922� −
Pseudomona aeruginosa ATCC 27853� −
Proteus vulgaris ATCC 13315� −
Staphylococcus epidermidis ATCC 1228� −
Results of Mu RPA of DNA extracts; “+” indicates a positive and “-” indicates a negative test results
�—ATCC bacterial strains obtained from the bacteriology unit of KCCR.
https://doi.org/10.1371/journal.pntd.0007155.t002
Table 3. Demographic and clinical characteristics of patients whose samples were used in the study.
No. (%) of total lesions (n = 79)
Sex
Male 38 (48)
Female 41 (52)
Sample type
FNA 24 (30)
Swab 55 (70)
Age in years
Median (IQR) 17 (10–42)
Type of Lesion
Nodule 12 (15)
Plaque 9 (11)
Edema 1 (2)
Ulcer 57 (72)
WHO Category of Lesion
I 32 (40)
II 29 (37)
III 18 (23)
IQR, Interquartile range; I, A single lesions� 5 cm in diameter; II, A single lesion 5–15 cm in diameter; III, A single
lesion >15 cm in diameter, multiple lesions, critical sites, osteomyelitis
https://doi.org/10.1371/journal.pntd.0007155.t003
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plotted the receiver operating characteristic (ROC) curve (Fig 4). The area under the curve
(AUC) was 88 (95% CI, 70–96).
Discussion
A major control strategy for BU is early detection and treatment, hinging on effective labora-
tory confirmation of suspected cases, since prevention is not possible in the absence of either
an effective vaccine or a clear understanding of the mode of transmission. New diagnostic
tools for confirmation of cases that can be implemented at the district health facility level
where most patients are treated is a priority for the WHO. Since its discovery in 2006 by Pie-
penburg and his colleagues [20], RPA has been explored for the molecular diagnosis of infec-
tious diseases caused by pathogenic bacteria such as methicillin-resistant Staphylococcus
aureus, group B streptococci, Francisella tulerensis, Yersinia pestis, Bacillus anthracis, Pseudo-
monas aeruginosa [21,22], Chlamydia trachomatis, Mycobacterium tuberculosis, Mycobacte-
rium avium subsp. paratuberculosis [12–14] and parasitic infections caused by Plasmodium
falciparum, Entamoeba histolytica, Leishmania donovani and Toxoplasma gondii and Schisto-
soma japonicum [23–28].
In this paper we have described the development of a rapid RPA test targeting the IS2404
gene of M. ulcerans that successfully detects all strains analyzed. The highest burden of Buruli
ulcer disease is in West Africa, but it is a global disease that has been reported in about 33
countries in Africa, South America and the Western Pacific regions including Asia and Austra-
lia, with about 15 countries reporting cases annually [29]. The ability of the RPA to detect all
strains from different parts of the globe makes it an optimal performance feature of a new diag-
nostic test for BU. The limit of detection using a molecular standard was 45 target copies.
While the analytical sensitivity is lower than that of real-time PCR (1–10 copies), we believe it
is still within the clinical detection range of most symptomatic BU patients, as demonstrated
by the high (88%) clinical sensitivity and specificity (100%) using clinical samples. The sensi-
tivity is higher than previously reported for laboratory tests currently available for use at the
district level, such as 40–60% [30,31] for smear microscopy detecting acid-fast bacilli and 73%
[32] for fluorescent thin-layer chromatography detecting mycolactone.
Several studies have demonstrated that bacterial super infections occur in Buruli ulcer
lesions. The most common bacteria isolates include Staphylococcus aureus, Pseudomonas aeru-
ginosa and Klebsiella pneumoniae [33–35]. When Mu-RPA was tested against a range of skin
contaminants including these, it showed high specificity for M. ulcerans, as well as failing to
Table 4. Clinical sensitivity and specificity of Mu-RPA compared to real-time PCR for IS2404 (stratified by type of sample used).
PCR +ve PCR–ve Total Sensitivity % (95% CI) Specificity % (95% CI) PPV % (95% CI) NPV % (95% CI)
Swab
Mu RPA +ve 33 0 33 92 (78–98) 100 (82–100) 100 (89–100) 86 (65–97)
Mu RPA–ve 3 19 22
FNA
Mu RPA +ve 18 0 18 82 (60–95) 100 (16–100) 100 (81–100) 33 (0.4–78)
Mu RPA–ve 4 2 6
Total
Mu RPA +ve 51 0 51 88 (77–95) 100 (84–100) 100 (93–100) 75 (55–89)
Mu RPA–ve 7 21 28
PPV, Positive predictive value; NPV, Negative predictive value; +ve, Positive; -ve, Negative
https://doi.org/10.1371/journal.pntd.0007155.t004
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react with any of the closely related mycobacteria tested. In this respect it was similar to the
PCR for IS2404 currently regarded as the gold standard for confirmation of BU disease.
A similar point of care method known as the Loop mediated isothermal amplification
method (LAMP) has comparable sensitivity to Mu-RPA but with a turnaround time of over 60
minutes for DNA amplification alone [9,10]. The assay employs six primers to amplify the
IS2404 gene at a high temperature of (60 ˚C). The results readout relies on changes in assay
turbidity, which is recognized by the naked eye or recorded in real-time by a portable device.
In contrast, the use of two opposing primers and a probe in the Mu-RPA allows exponential
amplification of target sequence with high efficiency similar to that of real-time PCR but it is
faster and more portable. The RPA can also be multiplexed for detection of other pathogens or
drug resistance profiles if required, a feature that is lacking with LAMP. Due to its simplicity
and the use of less energy intensive equipment suited for low resource setting, RPA has been
proposed as an alternative to PCR for point of care diagnosis of infectious diseases [24,36].
Like other isothermal techniques, RPA tolerates PCR inhibitors present in less purified sam-
ples [28,37], so it can be used with crude sample preparation techniques to facilitate diagnosis
in low resourced settings. This has not been assessed in the present study. Further studies will
be needed to fully evaluate the possible use of this assay with crude material, including careful
Fig 4. Receiver operating characteristic curve for the Mu-RPA assay. The x-axis shows the values for specificity and
the y axis, the values for sensitivity. The AUC was 88 (95% CI 70–96).
https://doi.org/10.1371/journal.pntd.0007155.g004
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consideration of biosafety, sensitivity and DNA contamination. There is also a need to exam-
ine simpler methods for disrupting mycobacterial cells to allow access to bacterial nucleic acid
either with reagent, small device or both.
Conclusion
A real-time RPA assay was developed for the rapid and accurate detection of M. ulcerans DNA
with high sensitivity, specificity and reproducibility comparable to real-time PCR. It was sig-
nificantly faster than available real-time PCR methods for detecting M. ulcerans with a run
time of 15 minutes, compared to almost 2 hours for real-time PCR. Potentially the Mu-RPA
can be used in a low resource setting closer to the patients when combined with a fast DNA
extraction method.
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